Cresco Labs Inc. (OTCMKTS:CRLBF) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Cresco Labs Inc. (OTCMKTS:CRLBF) have been given a consensus recommendation of “Moderate Buy” by the eight research firms that are presently covering the stock, Marketbeat.com reports. Four analysts have rated the stock with a hold rating, two have assigned a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $2.50.

Several research firms recently weighed in on CRLBF. Cormark downgraded shares of Cresco Labs from a “moderate buy” rating to a “hold” rating in a report on Monday, November 11th. Roth Capital raised Cresco Labs to a “strong-buy” rating in a research note on Sunday, November 10th. Finally, Atb Cap Markets lowered Cresco Labs from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 9th.

Cresco Labs Price Performance

Shares of CRLBF opened at $0.88 on Friday. The firm has a 50-day simple moving average of $1.30 and a two-hundred day simple moving average of $1.54. The stock has a market cap of $428.68 million, a PE ratio of -4.39 and a beta of 1.73. Cresco Labs has a 1-year low of $0.85 and a 1-year high of $2.65. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.97 and a quick ratio of 1.39.

Cresco Labs Company Profile

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.